Unspecified mood [affective] disorder
Methodology & AI Transparency ⓘ
Unspecified mood [affective] disorder Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Unspecified mood [affective] disorder—coded clinically as F39 across Depression & Mood guidelines—combines medication response pharmacogenomics [Unspecified mood [affective] disorder F39] with structured follow-up of Serum Vitamin D in Unspecified mood [affective] disorder (F39: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F39)).
- 2 Real-world patient consensus: Clinical coding for Unspecified mood [affective] disorder uses ICD-10 F39 across Depression & Mood specialty care.
- 3 Typical cash cost range: Differential triage of Unspecified mood [affective] disorder (F39) utilizes medication response pharmacogenomics [Unspecified mood [affective] disorder F39].
- 4 Top reported side effects / signs: Key Depression & Mood biomarkers for Unspecified mood [affective] disorder (F39): TSH & Free in Unspecified mood [affective] disorder (F39: T4 Rule-Out) & Serum Vitamin D in Unspecified mood [affective] disorder (F39: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F39)).
Ask our AI Specialists anything about Unspecified mood [affective] disorder
What Is Unspecified mood [affective] disorder?
Unspecified mood [affective] disorder—coded clinically as F39 across Depression & Mood guidelines—combines medication response pharmacogenomics [Unspecified mood [affective] disorder F39] with structured follow-up of Serum Vitamin D in Unspecified mood [affective] disorder (F39: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F39)).
Pathophysiology, Underlying Causes & Clinical Presentation
Unspecified mood [affective] disorder (F39) alters depression & mood homeostasis through hypothalamic-pituitary-adrenal (HPA) axis in Unspecified mood [affective] disorder (F39: cortisol hyperactivity); clinical remission targets Serum Vitamin D in Unspecified mood [affective] disorder (F39: & RBC Folate) within 25(OH)D 40 – 65 ng/mL (F39).
Common Symptoms & Clinical Signs
- • Presentation of Unspecified mood [affective] disorder (F39): slowed concentration, indecisiveness, in Unspecified mood [affective] disorder (F39: and physical heaviness)
- • Secondary Unspecified mood [affective] disorder clinical sign: loss of interest in Unspecified mood [affective] disorder (F39: or pleasure in)
- • Symptom flares in Unspecified mood [affective] disorder correlating with TSH & Free in Unspecified mood [affective] disorder (F39: T4 Rule-Out) deviation outside TSH 0.8 – 2.5 mIU/L (F39)
- • Functional depression & mood impact requiring medication response pharmacogenomics [Unspecified mood [affective] disorder F39] evaluation (F39)
Unspecified mood [affective] disorder Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F39 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Free in Unspecified mood [affective] disorder (F39: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F39) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Unspecified mood [affective] disorder (F39: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F39) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Unspecified mood [affective] disorder (F39: Score) | < 4 (clinical remission) (F39) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Unspecified mood [affective] disorder
Treatment selection for Unspecified mood [affective] disorder depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Unspecified mood [affective] disorder)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Which Antidepressant Gives You the Best Shot at Full Recovery? What a Major Review Found These results indicate that venlafaxine therapy is statistically superior to SSRIs as a class, but only to fluoxetine individually. Biological psychiatry • 2008-02-15 • Meta-Analysis | N = 3,621 | 99/100 | PMID 17888885 ↗ |
| New Insights on A Decision-Support System to Personalize Antidepressant Treatment in depression:: What a 540-Participant Study Found Of the 520 eligible participants, 493 were included in the primary analysis (median age, 35 [IQR, 25 to 48] years; 58% female; PHQ-9 mean score, 16.6 [SD, 5.1]; GAD-7 mean score, 11.5 [SD, 4.1]). JAMA • 2026-04-14 • Randomized Controlled Trial | N = 540 | 93/100 | PMID 41779422 ↗ |
| What the Latest Evidence Really Says About Meta-analysis on the efficacy outcomes of selective serotonin reuptake inhibitors Our meta-analysis supports the use of SSRIs for the alleviation of depression in patients with AD. BMC neurology • 2023-05-31 • Meta-Analysis | Multi-cohort | 92/100 | PMID 37259037 ↗ |
| Sertraline vs. Imipramine to prevent relapse: Which Works Better for Chronic depression? Most chronic depression patients who remit with 12 weeks of sertraline or imipramine treatment maintain full symptom relief during 16 weeks of continuation treatment. Journal of affective disorders • 2001-06-15 • Randomized Controlled Trial | N = 147 | 88/100 | PMID 11426506 ↗ |
| Can This Approach Help? Inside the Latest Research on Rosiglitazone Adjunct to Sertraline for depression: A Randomized, gold-standard Further long-term, large-scale studies are recommended to confirm this evidence. Depression and anxiety • 2026-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 42491722 ↗ |
Unspecified mood [affective] disorder Patient Community & “People Like Me” Threads
Filter Unspecified mood [affective] disorder community threads and patient logs by age, biological sex, dosage, and treatment duration.